Caracterización de eventos adversos y problemas relacionados con insulina reportados en Bogotá D. C. 2010-2017

Diabetes mellitus is a chronic disease that requires medical attention. According to the International Diabetes Federation (IDF) and the World Health Organization (WHO), the prevalence of diabetes in Colombia ranges between 7.1% and 8.5%. The present study aimed to describe the cases of Adverse even...

Full description

Autores:
Ballen Salamanca, Yeimy Andrea
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2017
Institución:
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
Repositorio:
Repositorio Institucional UDCA
Idioma:
spa
OAI Identifier:
oai:repository.udca.edu.co:11158/844
Acceso en línea:
https://repository.udca.edu.co/handle/11158/844
Palabra clave:
Insulina
Evento adverso
Problema relacionado con medicamento
Insulina -- Efectos secundarios
Diabetes -- Tratamiento con drogas
Rights
closedAccess
License
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
Description
Summary:Diabetes mellitus is a chronic disease that requires medical attention. According to the International Diabetes Federation (IDF) and the World Health Organization (WHO), the prevalence of diabetes in Colombia ranges between 7.1% and 8.5%. The present study aimed to describe the cases of Adverse events and insulin-related problems reported to the district pharmacovigilance program of Bogotá DC Colombia 2010-2017. Finally, 70 related problems were characterized and 49 adverse reactions of 125 reports obtained by the Bogota Pharmacovigilance district program during the period from 2010 to 2017, with the use of Insulin. The patients required hospitalization with 33.6%, with respect to age and pathology; the range of 65-69 that corresponds to the prevalence given in the onset of type II diabetes showed 7 cases, for type I diabetes reported from the range of 0-4 and for sex 68 notifications that correspond to gender to women. Most of the reports were produced by Insulina Humana, Glargina and Lispro, and are related to the road delivery system that corresponds 60% according to results obtained in the INVIMA search.